Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 2992-2999

  Knight, Daniel R ^a   Giglio, Steven ^b   Huntington, Peter G ^c   Korman, Tony M ^d   Kotsanas, Despina ^d   Moore, Casey V ^e   Paterson, David L ^f   Prendergast, Louise ^g   Huber, Charlotte A ^f   Robson, Jennifer ^h   Waring, Lynette ^g   Wehrhahn, Michael C ⁱ   Weldhagen, Gerhard F ^e   Wilson, Richard M ^b   Riley, Thomas V ^a,j  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Healthscope Pathology   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e SA Pathology   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g MELBOURNE PATHOLOGY   (Australia)

^h SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

ⁱ DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

^j PATHWEST LABORATORY MEDICINE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; MOXIFLOXACIN; TOXIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; FECES; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; RIBOTYPING; AUSTRALIA; CLASSIFICATION; CLOSTRIDIUM INFECTION; COMMUNITY ACQUIRED INFECTION; CROSS INFECTION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; GENETICS; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AUSTRALIA; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RIBOTYPING; YOUNG ADULT;

EID: 84945220114     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv220     Document Type: Article

References (42)

1. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359: 1932-40.
2. Hensgens MP, Keessen EC, Squire MM et al. Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect 2012; 18: 635-45.
3. Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol 2009; 7: 72-86.
4. Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis 2014; 5: 69-84.
5. Babakhani F, Seddon J, Sears P. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Antimicrob Agents Chemother 2014; 58: 2934-7.
6. Goldstein EJ, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012; 55 Suppl 2: S143-8.
7. Louie TJ, Emery J, KrulickiWet al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-3.
8. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9.
9. Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 Suppl 2: S132-42.
10. Goldstein EJ, Citron DM, Sears P et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011; 55: 5194-9.
11. Eyre DW, Babakhani F, Griffiths D et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014; 209: 1446-51.
12. He M, Miyajima F, Roberts P et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45: 109-13.
13. Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 1162-70.
14. Crobach MJ, Dekkers OM, Wilcox MH et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1053-66.
15. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20: 1-26.
16. Slimings C, Armstrong P, Beckingham WD et al. Increasing incidence of Clostridium difficile infection, Australia, 2011-2012. Med J Aust 2014; 200: 272-6.
17. Riley TV. Is Clostridium difficile a threat to Australia's biosecurity? Med J Aust 2009; 190: 661-2.
18. Eyre DW, Tracey L, Elliott B et al. Emergence and spread of predominantly community-onset Clostridium difficile PCR ribotype 244 infection in Australia, 2010 to 2012. Euro Surveill 2015; 20: pii=21059.
19. Bowman RA, Riley TV. Laboratory diagnosis of Clostridium difficile-associated diarrhoea. Eur J Clin Microbiol Infect Dis 1988; 7: 476-84.
20. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2011.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
22. EUCAST. Clinical Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 4.0. http://www.eucast.org/.
23. O'Connor JR, Galang MA, Sambol SP et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52: 2813-7.
24. Kato N, Ou CY, Kato H et al. Identification of toxigenic Clostridium difficile by the polymerase chain reaction. J Clin Microbiol 1991; 29: 33-7.
25. Stubbs S, Rupnik M, Gibert M et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186: 307-12.
26. Stubbs SL, Brazier JS, O'Neill GL et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-3.
27. Knight DR, Thean S, Putsathit P et al. Cross-sectional study reveals high prevalence of Clostridium difficile non-PCR ribotype 078 strains in Australian veal calves at slaughter. Appl Environ Microbiol 2013; 79: 2630-5.
28. Leroi MJ, Siarakas S, Gottlieb T. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur J Clin Microbiol Infect Dis 2002; 21: 72-4.
29. Lachowicz D, Pituch H, Obuch-Woszczatynski P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 2014; 31: 37-41.
30. Freeman J, Vernon J, Morris K et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 2014; 21: 248.e9-16.
31. Goldstein EJ, Citron DM, Tyrrell KL et al. Comparative in vitro activities of SMT19969, a newantimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 2013; 57: 4872-6.
32. Debast SB, Bauer MP, Sanders IM et al. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J Antimicrob Chemother 2013; 68: 1305-11.
33. Spigaglia P, Barbanti F, Mastrantonio P et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57: 784-9.
34. Tickler IA, Goering RV, Whitmore JD et al. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother 2014; 58: 4214-8.
35. Leeds JA, Sachdeva M, Mullin S et al. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 2014; 69: 41-4.
36. Foster NF, Collins DA, Ditchburn SL et al. Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study. New Microb New Infect 2014; 2: 64-71.
37. Bauer MP, Notermans DW, van Benthem BH et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
38. Knight DR, Squire MM, Riley TV. Clostridium difficile in Australian neonatal pigs: nationwide surveillance study shows high prevalence and heterogeneity of PCR ribotypes. Appl Environ Microbiol 2014; 81: 119-23.
39. Cheng V, Yam W, Lam O et al. Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis 2011; 30: 1371-81.
40. Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control 2013; 2: 21.
41. Planche T, Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol 2011; 64: 1-5.
42. Australian Commission on Safety and Quality in Health Care. Implementation Guide for Surveillance of Clostridium difficile Infection. Canberra: Commonwealth of Australia, 2011.